# Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome

> **NCT00394745** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 45 (actual)

## Conditions studied

- Hypertension
- Metabolic Syndrome

## Interventions

- **DRUG:** Valsartan

## Key facts

- **NCT ID:** NCT00394745
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00394745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00394745, "Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00394745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*